double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo
analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period
at 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was:
−12.3% with the 5-mg dose,
−18.7% with the 10-mg dose,
−19.7% with the 15-mg dose,
−1.3% among those who received placebo (P<0.001 for all comparisons with placebo)
fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001)
after 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001)
off treatment from tirzepatide, there was an estimated mean weight regain of 7% was observed over the 17-week off-treatment period
The study authors concluded that:
three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo
Reference:
Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. NEJM November 13, 2024
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.